Clinical Trials
47 trialsITHORinVHL
IRCCS San Raffaele
DANNIgene
Assistance Publique - Hôpitaux de Paris
BIOSUNTOX
University Hospital, Rouen
Kidney Cancer DNA Registry
Memorial Sloan Kettering Cancer Center
Mechanisms of Resistance to PSMA Radioligand Therapy
University of California, San Francisco
ELEPHAS-04
Mayo Clinic
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
University of Oklahoma
BRICCS
Mayo Clinic
Cancer DNA Detection in Blood and Urine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CHEMOPROST
Institut Bergonié
Early Ageing During Therapy in AYA Cancer Patients
University Medical Center Groningen
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
FUTURE
Assistance Publique Hopitaux De Marseille
Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer
Shanghai Changzheng Hospital
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Vanderbilt-Ingram Cancer Center
The Effect of IBD Flares on Serum PSA
Northwestern University
LUTRAC
Erasmus Medical Center
PROMECI
University Hospital, Tours
SoMuKT
IRCCS San Raffaele
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
Janssen Research & Development, LLC
PROMIC
Turku University Hospital
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
Memorial Sloan Kettering Cancer Center
CHARTER
Angle plc
IRSTB030
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
ANGIOCOR
Assistance Publique - Hôpitaux de Paris
CINECI
University Hospital, Tours
Bone Marrow Suppression and Recovery During Radionuclide Treatment
Rigshospitalet, Denmark
PROTECT
Radboud University Medical Center
ADOPT
University of Dundee
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
Saladax Biomedical, Inc.
Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes
UNC Lineberger Comprehensive Cancer Center
NEUROTAX
University Hospital, Tours
PROMPT
Radboud University Medical Center
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
Abramson Cancer Center at Penn Medicine
Circulating Tumor Cells in Prostate Cancer Patients
University of Texas Southwestern Medical Center
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
M.D. Anderson Cancer Center
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
Chronix Biomedical Corporation
Evaluation of Complex Renal Cyst With CEUS/Functional MRI Versus CT
Insel Gruppe AG, University Hospital Bern
Genetic Biomarker Discovery for Metastatic Prostate Cancer
Mayo Clinic
VPCA-B+PIV
Celsee Diagnostics
NISar
Odense University Hospital
Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
CTC
Comprehensive Cancer Centers of Nevada
BIOMETHS
The Christie NHS Foundation Trust
Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
Fudan University
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
CirCanCell
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari